Drug Type Small molecule drug |
Synonyms Lisuride, Lisuride maleate (JAN), Lisuride TDS + [5] |
Mechanism 5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists), 5-HT2A receptor agonists(Serotonin 2a (5-HT2a) receptor agonists), 5-HT2B receptor agonists(Serotonin 2b (5-HT2b) receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC24H30N4O5 |
InChIKeyCVQFAMQDTWVJSV-BAXNFHPCSA-N |
CAS Registry19875-60-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01462 | Lisuride Maleate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Parkinson Disease | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Restless Legs Syndrome | Phase 3 | DE | 23 Aug 2006 | |
Fragile X Syndrome | Preclinical | KR | 27 Oct 2022 |